Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference

GlobeNewswire

1小時前

BRIDGEWATER N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Alan Bash, interim Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference in New York, NY on Tuesday, September 15, 2026, at 2:35 p.m. ET.

The live webcast will be available to investors and other interested parties by accessing the Investor Relations section of the Legend Biotech website. The webcast replay will be available approximately 48 hours after the webcast.

ABOUT LEGEND BIOTECH

With over 3,000 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. Legend Biotech is at the forefront of the CAR-T cell therapy revolution with CARVYKTI^®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the United States, Legend Biotech is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, Legend Biotech plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.

Learn more at www.legendbiotech.com and follow us on X, Instagram, and LinkedIn.

INVESTOR CONTACT:
Caroline Paul
Tel: (973) 650-5832
Caroline.Paul@legendbiotech.com

PRESS CONTACT:
Kim Fox
Tel: (848) 388-8445
media@legendbiotech.com

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2664856297"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2664856297\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2664856297?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-01 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2664856297","market":"hk","top_or_hot":-1,"title":"Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference","media":"GlobeNewswire","content":"<html><body><p>BRIDGEWATER N.J., Sept.  01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Alan Bash, interim Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference in New York, NY on Tuesday, September 15, 2026, at 2:35 p.m. ET.</p> <p>The live webcast will be available to investors and other interested parties by accessing the Investor Relations section of the Legend Biotech website. The webcast replay will be available approximately 48 hours after the webcast.</p> <p><strong>ABOUT LEGEND BIOTECH</strong></p> <p>With over 3,000 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. Legend Biotech is at the forefront of the CAR-T cell therapy revolution with CARVYKTI<sup>®</sup>, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson &amp; Johnson. Centered in the United States, Legend Biotech is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, Legend Biotech plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.</p> <p>Learn more at www.legendbiotech.com and follow us on X, Instagram, and LinkedIn.</p> <p><strong>INVESTOR CONTACT:</strong><br/>Caroline Paul<br/>Tel: (973) 650-5832<br/>Caroline.Paul@legendbiotech.com</p> <p><strong>PRESS CONTACT:</strong><br/>Kim Fox<br/>Tel: (848) 388-8445<br/><u>media@legendbiotech.com</u></p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/ZTg0ZjkxMTItYTMzNS00MGZjLTgxYzEtMTlkNzgzZmU1MjI4LTEyMDY1MDUtMjAyNi0wOS0wMS1lbg==/tiny/Legend-Biotech-USA-Inc-.png\"/></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLegend Biotech to Participate in the Morgan Stanley Global Healthcare Conference\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1016364462\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">GlobeNewswire </p>\n<p class=\"h-time smaller\">2026-09-01 20:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p>BRIDGEWATER N.J., Sept.  01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Alan Bash, interim Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference in New York, NY on Tuesday, September 15, 2026, at 2:35 p.m. ET.</p> <p>The live webcast will be available to investors and other interested parties by accessing the Investor Relations section of the Legend Biotech website. The webcast replay will be available approximately 48 hours after the webcast.</p> <p><strong>ABOUT LEGEND BIOTECH</strong></p> <p>With over 3,000 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. Legend Biotech is at the forefront of the CAR-T cell therapy revolution with CARVYKTI<sup>®</sup>, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson &amp; Johnson. Centered in the United States, Legend Biotech is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, Legend Biotech plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.</p> <p>Learn more at www.legendbiotech.com and follow us on X, Instagram, and LinkedIn.</p> <p><strong>INVESTOR CONTACT:</strong><br/>Caroline Paul<br/>Tel: (973) 650-5832<br/>Caroline.Paul@legendbiotech.com</p> <p><strong>PRESS CONTACT:</strong><br/>Kim Fox<br/>Tel: (848) 388-8445<br/><u>media@legendbiotech.com</u></p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/ZTg0ZjkxMTItYTMzNS00MGZjLTgxYzEtMTlkNzgzZmU1MjI4LTEyMDY1MDUtMjAyNi0wOS0wMS1lbg==/tiny/Legend-Biotech-USA-Inc-.png\"/></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.globenewswire.com/news-release/2026/09/01/3354079/0/en/legend-biotech-to-participate-in-the-morgan-stanley-global-healthcare-conference.html","article_id":"2664856297","we_media_id":"1016364462","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2664856297","pubTimestamp":1788264000,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"GlobeNewswire","introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the world’s largest and most trusted newswires.","home_visible":1,"id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"summary":"BRIDGEWATER N.J., Sept.  01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Alan Bash, interim Chief Executi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MEMS":"MATTHEWS EMERGING MARKETS DISCOVERY ACTIVE ETF","FBT":"First Trust NYSE Arca Biotechnology Index Fund","BK4505":"高瓴资本持仓","XBI":"SPDR S&P Biotech ETF","CNCR":"Range Cancer Therapeutics ETF","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","IBB":"生物科技指数ETF-iShares Nasdaq","MEDI":"HARBOR HEALTH CARE ETF","BK4588":"碎股","TBXU":"Direxion Daily Biotech Top 5 Bull 2X ETF","LFSC":"F/m Emerald Life Sciences Innovation ETF","HCSG":"Healthcare Svcs Group Inc","IBBQ":"Invesco Nasdaq Biotechnology ETF","SYNB":"PUTNAM BIOREVOLUTION ETF","CANC":"TEMA ONCOLOGY ETF","BK4137":"综合支持服务","XLV":"健康照护类股ETF-SPDR","LEGN":"传奇生物","BK4581":"高盛持仓","GNOM":"Global X Genomics & Biotechnology ETF","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","LABU":"三倍做多标普生物-Direxion","BK4585":"ETF&股票定投概念"},"translate_title":"传奇生物将参加摩根士丹利全球医疗保健大会","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CNCR":0.75,"FBT":0.75,"MEMS":0.6,"XBI":1.5,"XLV":1.5,"TBXU":0.75,"LEGN":1.5,"MEDI":0.6,"HCSG":1.5,"LFSC":0.75,"CANC":0.6,"SYNB":0.75,"IBB":0.75,"LABU":0.6,"IBBQ":0.75,"GNOM":0.75},"content_text":"BRIDGEWATER N.J., Sept.  01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Alan Bash, interim Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference in New York, NY on Tuesday, September 15, 2026, at 2:35 p.m. ET. The live webcast will be available to investors and other interested parties by accessing the Investor Relations section of the Legend Biotech website. The webcast replay will be available approximately 48 hours after the webcast. ABOUT LEGEND BIOTECH With over 3,000 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. Legend Biotech is at the forefront of the CAR-T cell therapy revolution with CARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the United States, Legend Biotech is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, Legend Biotech plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities. Learn more at www.legendbiotech.com and follow us on X, Instagram, and LinkedIn. INVESTOR CONTACT:Caroline PaulTel: (973) 650-5832Caroline.Paul@legendbiotech.com PRESS CONTACT:Kim FoxTel: (848) 388-8445media@legendbiotech.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}